| Literature DB >> 31980029 |
Hannes Neuwirt1, Jan Bouchal2, Gvantsa Kharaishvili2, Christian Ploner3, Karin Jöhrer4,5, Florian Pitterl6, Anja Weber7, Helmut Klocker7, Iris E Eder8.
Abstract
BACKGROUND: Androgen receptor targeted therapies have emerged as an effective tool to manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy resistance represents a major challenge in the clinical management of patients, also because the molecular mechanisms behind therapy resistance are not yet fully understood. In the present study, we therefore aimed to identify novel targets to intervene with therapy resistance using gene expression analysis of PCa co-culture spheroids where PCa cells are grown in the presence of cancer-associated fibroblasts (CAFs) and which have been previously shown to be a reliable model for antiandrogen resistance.Entities:
Keywords: AKR1C3; Antiandrogens; Castration resistance; Cholesterol; HMGCS2; Prostate cancer; Simvastatin; Steroid metabolism
Mesh:
Substances:
Year: 2020 PMID: 31980029 PMCID: PMC6979368 DOI: 10.1186/s12964-019-0505-5
Source DB: PubMed Journal: Cell Commun Signal ISSN: 1478-811X Impact factor: 5.712
Clinical and pathologic characteristics of patients
| Parameter | Range | Tumor stage (number of patients) | |||
|---|---|---|---|---|---|
| pT1–2 | pT3–4 | N1 | Sum | ||
| Number of patients | 21 | 26 | 20 | 67 | |
| Age (years) | 49–59 | 8 | 8 | 7 | 23 |
| 60–69 | 11 | 15 | 12 | 38 | |
| 70–75 | 2 | 3 | 1 | 6 | |
| Tumor grade (Gleason score) | ≤ 6 | 7 | 3 | 1 | 11 |
| 7 | 13 | 13 | 9 | 35 | |
| ≥ 8 | 1 | 10 | 10 | 21 | |
| Serum PSA (ng/mL) | < 4 | 5 | 2 | 0 | 7 |
| 4–10 | 12 | 11 | 5 | 28 | |
| > 10 | 4 | 13 | 15 | 32 | |
Fig. 1Gene expression patterns of PCa spheroids with and without cancer-associated fibroblasts (CAFs). a Representative phase contrast images are shown for LNCaP and DuCaP PCa cells grown either in 75cm2 culture flasks (2D) or as 3D spheroids in 96 well hanging drop plates in the absence and (b) presence of GFP-expressing CAFs (magnification 10x, scale bar: 500 μm). Alterations in mRNA gene expression were determined via Illumina microarray analysis and the number of differentially expressed genes was represented in Venn diagrams. To determine gene expression changes that occur in PCa cells upon co-culture with CAFs, CAF-specific genes were subtracted. c Expression of HMGCS2 and AKR1C3 was validated by real-time RT-PCR in LNCaP and DuCaP monoculture spheroids and in LNCaP and DuCaP cells after spheroid co-culture with CAFs (LN/CAF, Du/CAF). Separation of cells was performed by flow cytometry-assisted cell sorting based on GFP expression in CAFs as described under methods. Values are expressed as relative expression of the gene of interest (GOI) normalized to hydroxymethylbilane synthase (HMBS). d Simplified overview of cholesterol and steroid biosynthesis metabolism. e Western blot analysis of HMGCS2 and AKR1C3 in mono vs co-culture spheroids. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control. Quantification of bands was performed with Image Studio (Li-Cor) and the ratio between the protein of interest and GAPDH was blotted in a graph. Data are represented as mean ± SEM from at least three independent experiments. (* P < 0.05, ** P < 0.01)
Genes similarly regulated in LNCaP and DuCaP 3D spheroids compared to 2D culture
| fold change 3D vs 2D | |||
|---|---|---|---|
| Symbol | LNCaP | DuCaP | Name |
| ANKHD1 | 2.00 | 2.38 | ankyrin repeat and KH domain containing 1 |
| CCPG1 | 2.47 | 2.78 | cell cycle progression 1 |
| FERMT2 | 2.43 | 5.05 | fermitin family member 2 |
| GDF15 | 2.40 | 11.10 | growth differentiation factor 15 |
| HSPH1 | 2.13 | 2.31 | heat shock protein family H, member 1 |
| LARP6 | 3.82 | 2.51 | La ribonucleoprotein domain family member 6 |
| MYLIP | 2.32 | 2.05 | myosin regulatory light chain interacting protein |
| PLAUR | 2.03 | 2.93 | plasminogen activator, urokinase receptor |
| PPARG | 2.15 | 11.33 | peroxisome proliferator-activated receptor gamma |
| SAT1 | 2.41 | 3.07 | spermidine/spermine N1-acetyltransferase 1 |
| SH3GLB1 | 2.11 | 3.50 | SH3-domain GRB2-like endophilin B1 |
| SLC3A2 | 2.23 | 3.51 | solute carrier family 3 (amino acid transporter heavy chain), member 2 |
| SPIRE1 | 2.86 | 2,44 | spire-type actin nucleation factor 1 |
| SQSTM1 | 2.57 | 3.00 | sequestosome 1 |
| TRIB3 | 2.34 | 2.08 | tribbles pseudokinase 3 |
| UPP1 | 2.39 | 2.62 | uridine phosphorylase 1 |
| ZFAND2A | 2.04 | 2.11 | zinc finger, AN1-type domain 2A |
| ZYX | 3.61 | 4.09 | zyxin |
| CDC45L | 0.17 | 0.45 | cell division cycle 45 |
| CHEK1 | 0.41 | 0.48 | checkpoint kinase 1 |
| E2F2 | 0.36 | 0.43 | E2F transcription factor 2 |
| EGR1 | 0.15 | 0.10 | early growth response 1 |
| FOS | 0.10 | 0.04 | FBJ murine osteosarcoma viral oncogene homolog |
| FOXM1 | 0.47 | 0.31 | forkhead box M1 |
| GINS2 | 0.25 | 0.44 | GINS complex subunit 2 (Psf2 homolog) |
| H2AFX | 0.46 | 0.38 | H2A histone family member X |
| HMMR | 0.18 | 0.49 | hyaluronan mediated motility receptor |
| ID3 | 0.45 | 0.25 | inhibitor of DNA binding 3, dominant negative helix-loop-helix protein |
| KIAA0101 | 0.29 | 0.48 | KIAA0101 |
| KIF11 | 0.44 | 0.49 | kinesin family member 11 |
| LOC731314 | 0.27 | 0.37 | similar to H2A histone family, member X |
| NCAPD2 | 0.46 | 0.45 | Condensin complex subunit 1 |
| PFKFB4 | 0.43 | 0.45 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 |
| SLC45A3 | 0.41 | 0.42 | solute carrier family 45 member 3 |
| TK1 | 0.30 | 0.44 | thymidine kinase 1, soluble |
| TYMS | 0.26 | 0.49 | thymidylate synthetase |
| UHRF1 | 0.31 | 0.43 | ubiquitin-like with PHD and ring finger domains 1 |
| TPX2 | 0.44 | 0.40 | TPX2, microtubule-associated |
| TUBA1A | 0.37 | 0.46 | tubulin alpha 1a |
Genes differentially expressed in Du/CAF (DuCaP co-cultured with CAFs) and LN/CAF (LNCaP co-cultured with CAFs) compared to DuCaP and LNCaP monoculture spheroids
| Symbol | Du/CAF vs DuCaP | LN/CAF vs LNCaP | Name |
|---|---|---|---|
| Fold change | |||
| SERPINA3 | 87.87 | 9.26 | Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin) |
| CFB | 87.73 | 7.24 | Complement factor B |
| FGL1 | 21.10 | 6.70 | Fibrinogen-like 1 (FGL1) |
| PLA2G2A | 20.41 | 2.83 | Phospholipase A2, group IIA (platelets, synovial fluid) |
| HMGCS2 | 19.79 | 5.43 | 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) |
| HLA-DRA | 14.19 | 2.50 | Major histocompatibility complex, class II, DR alpha |
| COL6A3 | 11.12 | 2.81 | Collagen, type VI, alpha 3 |
| IL32 | 11.07 | 3.80 | interleukin 32 (IL32), transcript variant 4, mRNA. |
| TGFBI | 10.72 | 3.04 | Transforming growth factor, beta-induced, 68 kDa |
| IRF1 | 9.80 | 2.73 | Interferon regulatory factor 1 |
| TAPBP | 9.45 | 2.88 | TAP binding protein (tapasin) |
| SCNN1A | 9.06 | 2.14 | Sodium channel, nonvoltage-gated 1 alpha |
| MMP7 | 8.97 | 2.57 | Matrix metallopeptidase 7 (matrilysin, uterine) |
| STAT3 | 8.90 | 3.05 | Signal transducer and activator of transcription 3 (acute-phase response factor) |
| TAP1 | 5.08 | 2.41 | Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) |
| JUNB | 4.81 | 2.19 | Jun B proto-oncogene |
| COL3A1 | 4.62 | 2.09 | Collagen, type III, alpha 1 |
| MALL | 4.43 | 2.81 | Mal, T-cell differentiation protein-like |
| DDR1 | 4.15 | 2.05 | Discoidin domain receptor tyrosine kinase 1 |
| CPB1 | 3.78 | 2.88 | Carboxypeptidase B1 (tissue) |
| CGN | 3.60 | 2.21 | Cingulin |
| GRHL2 | 3.46 | 2.46 | Grainyhead-like 2 (Drosophila) |
| CD276 | 3.34 | 2.22 | CD276 molecule |
| CYP2J2 | 3.31 | 2.59 | Cytochrome P450, family 2, subfamily J, polypeptide 2 |
| GPER | 3.24 | 2.60 | G protein-coupled estrogen receptor 1 |
| GRINA | 3.23 | 2.28 | Glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding) |
| UBE1 | 3.09 | 2.26 | Ubiquitin-activating enzyme E1 |
| VWA1 | 3.06 | 2.01 | von Willebrand factor A domain containing 1 |
| NFKB1 | 3.04 | 2.30 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
| HIPK2 | 2.92 | 2.09 | Homeodomain interacting protein kinase 2 |
| ATP1A1 | 2.85 | 2.60 | ATPase, Na+/K+ transporting, alpha 1 polypeptide |
| ABCC5 | 2.80 | 2.09 | ATP-binding cassette, sub-family C (CFTR/MRP), member 5 |
| EIF4G1 | 2.78 | 2.74 | Eukaryotic translation initiation factor 4 gamma, 1 |
| TMEM79 | 2.74 | 2.32 | Transmembrane protein 79 |
| FRMD8 | 2.74 | 2.08 | FERM domain containing 8 |
| ALDH3B2 | 2.73 | 2.29 | Aldehyde dehydrogenase 3 family, member B2 |
| ANKFY1 | 2.71 | 2.08 | Ankyrin repeat and FYVE domain containing 1 |
| MAP 1B | 2.62 | 2.51 | Microtubule-associated protein 1B |
| LRG1 | 2.60 | 2.07 | Leucine-rich alpha-2-glycoprotein 1 |
| MYH9 | 2.54 | 2.02 | Myosin, heavy chain 9, non-muscle |
| DHCR24 | 2.54 | 2.35 | 24-dehydrocholesterol reductase |
| CANT1 | 2.49 | 2.06 | Calcium activated nucleotidase 1 |
| UBA1 | 2.43 | 2.09 | Tubulin, alpha 1a |
| IDH2 | 2.42 | 2.40 | Isocitrate dehydrogenase 2 (NADP+) mitochondrial, nuclear gene encoding mitochondrial protein |
| RTN1 | 2.38 | 2.03 | Reticulon 1 |
| DHCR7 | 2.31 | 2.23 | 7-dehydrocholesterol reductase |
| VCP | 2.31 | 2.52 | Valosin-containing protein |
| MVP | 2.23 | 2.05 | Major vault protein |
| PROM2 | 2.19 | 2.21 | Prominin 2 |
| DTX2 | 2.16 | 2.11 | Deltex homolog 2 (Drosophila) |
| UBE2G1 | 2.11 | 2.01 | Ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, yeast) |
| DYNC1H1 | 2.11 | 2.30 | Dynein, cytoplasmic 1, heavy chain 1 |
| TPR | 2.08 | 2.12 | Translocated promoter region (to activated MET oncogene) |
| TGFBR3 | 2.08 | 3.76 | Transforming growth factor, beta receptor III |
| EIF2C2 | 2.08 | 2.02 | Eukaryotic translation initiation factor 2C, 2 |
| EPHX1 | 2.07 | 2.60 | Epoxide hydrolase 1, microsomal (xenobiotic) |
| PLEKHF1 | 2.06 | 2.48 | Pleckstrin homology domain containing, family F (with FYVE domain) member 1 |
KEGG pathways with XD scores > 0.96 in Du/CAF vs DuCaP spheroids
| Annotation (pathway/process) | XD score |
|---|---|
| hsa00053: Ascorbate and aldarate metabolism | 1.891 |
| hsa00040: Pentose and glucuronate interconversions | 1.705 |
| hsa00360: Phenylalanine metabolism | 1.621 |
| hsa00100: Steroid biosynthesis | 1.489 |
| hsa00140: Steroid hormone biosynthesis | 1.371 |
| hsa00980: Metabolism of xenobiotics by cytochrome p450 | 1.252 |
| hsa04966: Collecting duct acid secretion | 1.171 |
| hsa00982: Drug metabolism - cytochrome P450 | 1.092 |
| hsa00860: Porphyrin and chlorophyll metabolism | 1.085 |
| hsa00511: Other glycan degradation | 1.059 |
| hsa00120: Primary bile acid biosynthesis | 1.059 |
| hsa00500: Starch and sucrose metabolism | 1.024 |
| hsa00983: Drug metabolism - other enzymes | 0.991 |
Differentially regulated genes annotated to steroid biosynthesis in Du/CAF co-culture spheroids
| Symbol | Fold change | Name |
|---|---|---|
| AKR1C4 | 6.77 | Aldo-keto reductase family 1, member C4 |
| HSD11B2 | 5.37 | Hydroxysteroid (11-beta) dehydrogenase 2 |
| UGT1A1 | 5.22 | UDP glucuronosyltransferase 1 family, polypeptide A1 |
| AKR1C3 | 4.06 | Aldo-keto reductase family 1, member C3 |
| UGT1A3 | 3.04 | UDP glucuronosyltransferase 1 family, polypeptide A3 |
| DHCR7 | 2.31 | 7-dehydrocholesterol reductase |
| DHCR24 | 2.54 | 24-dehydrocholesterol reductase |
| LSS | 2.34 | Lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) |
| HSD17B7 | 2.11 | Hydroxysteroid (17-beta) dehydrogenase 7 |
| SC4MOL | 2.41 | Sterol-C4-methyl oxidase-like |
| SC5DL | 2.60 | Sterol-C5-desaturase (ERG3 delta-5-desaturase homolog, S. cerevisiae)-like |
| UGT2B11 | 2.31 | UDP glucuronosyltransferase 2 family, polypeptide B11 |
| CYP3A5 | 2.61 | Cytochrome P450, family 3, subfamily A, polypeptide 5 |
| HSD17B7 | 2.11 | Hydroxysteroid (17-beta) dehydrogenase 7 |
| UGT2B7 | 2.74 | UDP glucuronosyltransferase 2 family, polypeptide B7 |
| UGT2B10 | 2.57 | UDP glucuronosyltransferase 2 family, polypeptide B10 |
| UGT2B17 | 2.53 | UDP glucuronosyltransferase 2 family, polypeptide B17 |
| UGT1A6 | 0.42 | UDP glucuronosyltransferase 1 family, polypeptide A6 |
Fig. 2HMGCS2 and AKR1C3 expression is increased in PCa cells by incubation with CAF-conditioned medium. a mRNA expression of HMGCS2 and AKR1C3 was analyzed in LNCaP and DuCaP cells after 8 days of 3D spheroid culture in CAF-conditioned (CM) medium and compared to cells, which were cultured in standard medium. HMBS was used as internal control. Data represent the mean plus SEM from at least three independent experiments. (* P < 0.05, ** P < 0.01,*** P < 0.001) (b) Conditioned medium of CAF 3D spheroids was loaded onto a semi-quantitative RayBio® Human Cytokine Antibody Array (G-Series 1000, RayBiotech, Norcross, GA). Values were normalized to culture medium and expressed as mean signal intensity with SEM from three independent experiments. c CAFs were cultured either in T75 flasks (2D) or in 96 well hanging drop plates at 8000 cells per well. Alterations in mRNA gene expression were determined via Illumina microarray analysis. Significantly altered pathways between 2D and 3D cultured CAFs were identified via KEGG analysis. Representative phase contrast images are shown for CAFs grown either in 75cm2 culture flasks (2D) or as 3D spheroids in 96 well hanging drop plates (magnification 10x, scale bar: 500 μm)
Genes differentially regulated in 3D CAF spheroids compared to 2D culture
| Inflammation | |
|---|---|
| IL1B | Interleukin 1, beta |
| PTGS2 | Prostaglandin-endoperoxide synthase 2 |
| CXCL5 | Chemokine (C-X-C motif) ligand 5 |
| IL11 | Interleukin 11 |
| IL24 | Interleukin 24 |
| CXCL2 | Chemokine (C-X-C motif) ligand 2 |
| IL13RA2 | Interleukin 13 receptor, alpha 2 |
| IL6 | Interleukin 6 |
| CCL20 | Chemokine (C-C motif) ligand 20 |
| IL24 | Interleukin 24 |
| IL8 | Interleukin 8 |
| IL1A | Interleukin 1, alpha |
| IL33 | Interleukin 33 |
| CCL7 | Chemokine (C-C motif) ligand 7 |
| IRAK2 | Interleukin-1 receptor-associated kinase 2 |
| IL18R1 | Interleukin 18 receptor 1 |
| IL1R1 | Interleukin 1 receptor, type I |
| TNFAIP3 | Tumor necrosis factor, alpha-induced protein 3 |
| CCRL1 | Chemokine (C-C motif) receptor-like 1 |
| LOC651872 | C-C chemokine receptor type 11 (C-C CKR-11) |
| ISG20 | Interferon stimulated exonuclease gene 20 kDa |
| CXCL1 | Chemokine (C-X-C motif) ligand 1 |
| IL4R | Interleukin 4 receptor |
| TNFAIP6 | Tumor necrosis factor, alpha-induced protein 6 |
| IL1RN | Interleukin 1 receptor antagonist |
| INSIG1 | Insulin induced gene 1 |
| TNFSF10 | Tumor necrosis factor (ligand) superfamily, member 10 |
| CCL3L1 | Chemokine (C-C motif) ligand 3-like 1 |
| PTGER4 | Prostaglandin E receptor 4 (subtype EP4) |
| IL1F9 | Interleukin 1 family, member 9 |
| CCL3L1 | Chemokine (C-C motif) ligand 3-like 1 |
| IL7R | Interleukin 7 receptor |
| IL23A | Interleukin 23, alpha subunit p19 |
| IFRD1 | Interferon-related developmental regulator 1 |
| INSIG2 | Insulin induced gene 2 |
| ECM-receptor interaction | |
| TNC | Tenascin C (hexabrachion) |
| LAMB3 | Laminin, beta 3 |
| THBS2 | Thrombospondin 2 |
| COL4A6 | Collagen, type IV, alpha 6 |
| COL4A1 | Collagen, type IV, alpha 1 |
| ITGA2 | Integrin, alpha 2 (CD49B) |
| COL4A2 | Collagen, type IV, alpha 2 |
| Fatty acid metabolism | |
| ACSL4 | Acyl-CoA synthetase long-chain family member 4 |
| ACADVL | Acyl-Coenzyme A dehydrogenase, very long chain |
| ACSL1 | Acyl-CoA synthetase long-chain family member 1 |
Fig. 3Representative Western blots of HMGCS2 and AKR1C3 in various PCa cell lines after conventional 2D culture. Enzalutamide resistant sublines (EnzaR) were established through long-term culture of parental cells in the presence of 8 μM enzalutamide. Quantification of bands was performed with Image Studio (Li-Cor) and the ratio between the protein of interest and GAPDH was blotted in a graph. Data represent the mean plus SEM from at least three independent experiments. (* P < 0.05, ** P < 0.01,*** P < 0.001)
Fig. 4HMGCS2 and AKR1C3 expression is significantly increased in human PCa. a, b Representative staining for HMGCS2 and AKR1C3 in benign (BPH) prostate tissue and PCa. Staining intensity was quantified by determining H-score in the epithelium (ep) (a) and in the stroma (str) (b) as described under methods. c Expression of HMGCS2 and AKR1C3 was correlated with Gleason score (GSC) (GSC ≤ 6: N = 12, GSC = 7: N = 31, GSC ≥ 8: N = 19) and (d) lymph node metastases (N0: N = 41, N1: N = 20). Data are represented as mean + SEM. (* P < 0.05, *** P < 0.001)
Fig. 5Effects of HMGCS2 knockdown and overexpression on PCa cell growth. a LNCaPabl cells were stably infected with a doxycycline-inducible shHMGCS2 vector (ABLshHMGCS2). Following treatment with 1 μM doxycycline, HMGCS2 was effectively downregulated on protein level compared to the mock control as shown by Western analysis. GAPDH was used as loading control. b ABLshHMGCS2 cells were seeded into 96 well plates and incubated in the absence or presence of doxycycline over 5 days. Cell viability was determined with CellTiterGlo viability assay (Promega). Representative images were taken at the end of treatment (magnification 10x). c ABLshHMGCS2 cells were seeded into ULC 96 well plates (Corning) and allowed to form spheroids over 4 days. Then, 1 μM doxycycline (dox) and 5 μM enzalutamide (enza) were added. Cell viability was determined through CellTiterGlo viability assay after 10 days of treatment. Medium was exchanged twice a week. Representative images were taken at day 10 with IncuCyte S3 software. d LNCaP cells were transiently transfected with a HMGCS2 plasmid (LNCaP_HMGCS2). HMGCS2 overexpression was confirmed 72 h afterwards by Western blotting. GAPDH was used as internal control. e LNCaP cells were transiently transfected with a HMGCS2 plasmid and seeded into a 96 well ULC plate (Corning) to allow 3D spheroid formation. After 4 days, 5 μM enzalutamide was added in RPMI with 10% CS_FCS. After 10 days, cell viability was measured via CellTiterGlo assay. Representative images were taken at the end of treatment with IncuCyte S3 software. Data represent the mean plus SEM from at least three independent experiments. (* P < 0.05, ** P < 0.01)
Fig. 6Combined blockade of cholesterol and steroid biosynthesis with simvastatin and AKRi to inhibit PCa cells. Du/CAF (a) and LN/CAF (b) co-culture spheroids were established as described under methods. CAFs stably express GFP to distinguish them from tumor cells. Four days after seeding, spheroids were treated with 5 μM enzalutamide (enza), 5 μM simvastatin (sim), and 50 μM of an inhibitor against AKR1C3 (AKRi) in medium supplemented with 10% CS_FCS. Cell viability was assessed after 10 days using CellTiterGlo assay. (c, d, e) DuCaP EnzaR, CWR22Rv1, and LNCaPabl EnzaR were seeded into 96 well plates. After overnight incubation, drugs were added in medium with 10% CS_FCS as indicated. Representative images were taken after 6 days of treatment with 5 μM simvastatin and cropped to show typical rounded cells that were depicted with a black arrow. Cell viability was determined after 6 days via CellTiterGlo cell viability assay and expressed as mean relative luminescence units (RLU) from at least 3 independent experiments with SEM. f DuCaP EnzaR were seeded into 96 well plates. Treatment with 5 μM simvastatin was performed in RPMI + 10% FCS. Cell viability was determined after 6 days of treatment via CellTiterGlo cell viability assay and expressed as mean relative luminescence units (RLU) from at least three independent experiments with SEM. (* and + P < 0.05, ** and ++ P < 0.01, *** and +++ P < 0.001, * related to mock control, + related to enzalutamide-treated cells)
Fig. 7Schematic diagram showing combined targeting of cholesterol and steroid biosynthesis with simvastatin and AKRi in PCa co-culture spheroids